SABCS 2023 - Complete program listing
December 2023
Entire series of talks and interviews from the 5 days of the 2023 San Antonio Breast Cancer Symposium (SABCS) from December 5th to the 9th
DAY 1
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma - Day 1
Olaparib front line therapy with endocrine therapy in locally advanced unresectable or in metastatic breast cancer: OFELIA TRIAL
Screening for health related social needs, and now what? With Barbara Segarra-Vasquez DHSc
Key points from the SABCS session on Prevention, early detection and interception
Precocious modulation of metabolic and immunological parameters predicts tumor response to fasting-mimicking diet plus chemotherapy in patients with early stage TNBC
DAY 2
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma
Loco-regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304.
Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative breast cancer and residual tumor
Evaluating chemotherapy receipt and candidacy for PARP inhibitors in germline BRCA1/2 carriers with early and locally advanced breast cancer
DAY 3
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma - PART 1
Daily Review from SABCS 2023 with Dr. Jamil Asselah & Dr. Kim Ma - PART 2
Prognostic Impact of Adjuvant Trastuzumab for the Treatment of Localized Stage I Breast Cancer - Single Tertiary Center Experience
Neoadjuvant chemotherapy in invasive lobular carcinoma of the breast: A retrospective study on survival outcomes
DAY 4
Daily Review from SABCS 2023 with Dr. Jamil Asselah, Dr. Esfahani, and Dr. Tarantino.
Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
MedTalk from SABCS 2023 with Dr. Jean-Simon Fortin and Dr. Nagi S. El Saghir
DAY 5
Fertility preservation and assisted reproductive technologies in breast cancer patients interrupting adjuvant endocrine therapy to attempt pregnancy
Exploring Pioneering Initiatives: Tailoring Patient-Centric Solutions for a Diverse Cohort in the UAE
Essential findings of the INAVO120 primary analysis
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of ECOG-ACRIN 4112
Comments (0)